UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer

Annals of oncology, 2015-02, Vol.26 (2), p.354-362

2015

Volltextzugriff (PDF)

Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)

European journal of cancer (1990), 2014-01, Vol.50 (2), p.302-308

2014

Volltextzugriff (PDF)

Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab

Lung cancer (Amsterdam, Netherlands), 2012-06, Vol.76 (3), p.410-415

2012

Volltextzugriff (PDF)

Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S36-S36

2014

Volltextzugriff (PDF)

253 Phase 1 correlative study of ARQ761, a β-lapachone analogue that promotes NQ01-mediated programmed cancer cell necrosis

European journal of cancer (1990), 2014-11, Vol.50, p.84-85

2014

Volltextzugriff (PDF)

The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2002-09, Vol.37 (3), p.303-309

2002

Volltextzugriff (PDF)

Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508)

Annals of oncology, 2017-12, Vol.28 (12), p.3037-3043

2017

Volltextzugriff (PDF)

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer

Annals of oncology, 2014-01, Vol.25 (1), p.132-138

2014

Volltextzugriff (PDF)

SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15

Oncogene, 2012-09, Vol.31 (37), p.4107-4116

2012

Volltextzugriff (PDF)

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes

Lung cancer (Amsterdam, Netherlands), 2005, Vol.47 (1), p.69-80

2005

Volltextzugriff (PDF)

Efficacy and Safety of Single-Agent Axitinib (AG-013736; AG) in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC): A Phase II Trial

Clinical lung cancer, 2007-07, Vol.8 (7), p.452-452

2007

Volltextzugriff (PDF)

Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC): Metastatic Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S36-S36

2014

Volltextzugriff (PDF)

711 POSTER Sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors: a phase I dose-escalation and pharmacokinetic (PK) study

European journal of cancer supplements, 2007, Vol.5 (4), p.110-110

2007

Volltextzugriff (PDF)

Using Liquid Crystals to Report Membrane Proteins Captured by Affinity Microcontact Printing from Cell Lysates and Membrane Extracts

Journal of the American Chemical Society, 2005-06, Vol.127 (25), p.8912-8913

2005

Volltextzugriff (PDF)

6551 POSTER Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial

European journal of cancer supplements, 2007, Vol.5 (4), p.373-373

2007

Volltextzugriff (PDF)

Randomised Phase II Study of Axitinib or Bevacizumab Combined with Paclitaxel/Carboplatin (PAC/CARB) as First-Line Therapy for Patients (PTS) with Advanced Non–Small Cell Lung Cancer (NSCLC)

Annals of oncology, 2012-09, Vol.23, p.ix408

2012

Volltextzugriff (PDF)

Updates in Advances in Lung Cancer

Schiller, Joan H

1. Aufl., 1997

Volltextzugriff (PDF)

Adaptive QoS for mobile Web services through cross-layer communication

Computer (Long Beach, Calif.), 2007-02, Vol.40 (2), p.59-63

2007

Volltextzugriff (PDF)

O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599

Lung cancer (Amsterdam, Netherlands), 2005-07, Vol.49, p.S31-S31

2005

Volltextzugriff (PDF)

CMR 2005: 3.08: Preliminary imaging results with NM404 in lung cancer patients

Contrast media and molecular imaging, 2006-03, Vol.1 (2), p.60-61

2006

Volltextzugriff (PDF)

Quality of service in mobile and wireless networks: the need for proactive and adaptive applications

Proceedings of the 33rd Annual Hawaii International Conference on System Sciences, 2000, p.10 pp.

2000

Volltextzugriff (PDF)

Efficacy of reduced dose of IV topotecan (T) in relapsed small cell lung cancer (SCLC) patients

Lung cancer (Amsterdam, Netherlands), 2000-09, Vol.29 (1), p.10-10

2000

Volltextzugriff (PDF)

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer: Results from an ECOG prospective randomized trial of postoperative adjuvant therapy (E3590, INT0015)

Lung cancer (Amsterdam, Netherlands), 2000-09, Vol.29 (1), p.183-183

2000

Volltextzugriff (PDF)

CrossTalk: cross-layer decision support based on global knowledge

IEEE communications magazine, 2006-01, Vol.44 (1), p.93-99

2006

Volltextzugriff (PDF)

A flexible co-processor for high-performance communication support

Proceedings of GLOBECOM '95, 1995, Vol.2, p.1445-1449 vol.2

Schiller, J.H.

1995

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(44)

Publikationsform

Sprache

Englisch
(46)

Erscheinungsjahr

n.n

Thema

Science & Technology
(20)
Life Sciences & Biomedicine
(16)
Humans
(13)
Male
(10)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(9)
Female
(9)
Hematology, Oncology And Palliative Medicine
(9)
Oncology
(9)
Biological And Medical Sciences
(8)
Lung Neoplasms - Drug Therapy
(8)
Middle Aged
(8)
Adult
(7)
Medical Sciences
(7)
Aged
(6)
Chemotherapy
(5)
Animals
(4)
Application Software
(4)
Carcinoma, Non-Small-Cell Lung - Mortality
(4)
Carcinoma, Non-Small-Cell Lung - Pathology
(4)
Disease-Free Survival
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer

Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)

Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab

Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

253 Phase 1 correlative study of ARQ761, a β-lapachone analogue that promotes NQ01-mediated programmed cancer cell necrosis

The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer

Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508)

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer

SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes

Efficacy and Safety of Single-Agent Axitinib (AG-013736; AG) in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC): A Phase II Trial

Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC): Metastatic Non-Small Cell Lung Cancer

711 POSTER Sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors: a phase I dose-escalation and pharmacokinetic (PK) study

Using Liquid Crystals to Report Membrane Proteins Captured by Affinity Microcontact Printing from Cell Lysates and Membrane Extracts

6551 POSTER Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial

Randomised Phase II Study of Axitinib or Bevacizumab Combined with Paclitaxel/Carboplatin (PAC/CARB) as First-Line Therapy for Patients (PTS) with Advanced Non–Small Cell Lung Cancer (NSCLC)

Updates in Advances in Lung Cancer

Adaptive QoS for mobile Web services through cross-layer communication

O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599

CMR 2005: 3.08: Preliminary imaging results with NM404 in lung cancer patients

Quality of service in mobile and wireless networks: the need for proactive and adaptive applications

Efficacy of reduced dose of IV topotecan (T) in relapsed small cell lung cancer (SCLC) patients

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer: Results from an ECOG prospective randomized trial of postoperative adjuvant therapy (E3590, INT0015)

CrossTalk: cross-layer decision support based on global knowledge

A flexible co-processor for high-performance communication support

Suchergebnisse filtern